91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

Home

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

Language

Toggle Nav

My Cart

Search

Account

Settings

Language

Home
Applications
Protein Biology
Flow Cytometry
Adalimumab (anti-TNF-alpha)

Adalimumab (anti-TNF-alpha)

In stock

Adalimumab (anti-TNF-alpha)

MSDS

COA

Stock Information

Item (SKU)	Specifications	Is In Stock
A412002-100μg (Trial Size) Apply for free trial size（?） The same customer can apply for trial packaging three times a year, while the same product can only apply for trial packaging once a year	100μg	Out of Stock
A412002-1mg	1mg	Out of Stock
A412002-5mg	5mg	Out of Stock
A412002-10mg	10mg	Out of Stock

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Basic Information

Name	Adalimumab (anti-TNF-alpha)
Specifications & Purity	98%
Specificity	TNFSF2/TNFa
Species reactivity（Reacts with)	Cynomolgus,Human,Mouse?,Rhesus Macaque

Product Properties

Antibody Type	Primary antibody
Format	Whole IgG
Isotype	Human IgG1
Light Chain Type	Kappa
SDS-PAGE	145.5 kDa
Purification Method	Protein A purified
Purity	>95%
Form	Liquid
Storage buffer/Formulation	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
Preservatives	No
Concentration	Lot by Lot
Stability and Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS Number	331731-18-1

Database links

Wikipedia	Adalimumab
IMGT/mAb-DB	165
PubChem SID	178101561
PEP	adalimumab

Associated Ligand

Ligand ID

4860

ligand_name

adalimumab

synonyms

Humira®

ligand_type

Antibody

iupac_name

4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide

bioactivity_comments

The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).

comments

Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity . It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab have been deposited to the RCSB Protein Data Bank (IDs 4NYL and 3WD5 respectively).

Biosimilars:

Name	Trade name	Company	Clinical Phase	Indications
adalimumab-atto; ABP 501	Amjevita; Amgevita	Amgen	Approved (2016 FDA, 2017 EMA)	As per reference agent
adalimumab-adbm; BI 695501	Cyltezo	Boehringer Ingelheim	Approved (2017 FDA and EMA)	As per reference agent
ZRC-3197	Exemptia	Cadila Healthcare	Approved (2015 India)	Rheumatoid arthritis
adalimumab-bwwd; SB5	Hadlima	Samsung Bioepis	Approved (2019 FDA)	As per originator reference agent
adalimumab-aacf: MSB11022	Idacio; Kromeya	Fresenius Kabi	Approved (2019 EMA, 2022 FDA)	As per originator reference agent
BCD-057		Biocad	Ph 3 (NCT02762955)	Plaque psoriasis
adalimumab-adaz; GP2017	Hyrimoz; Hefiya; Halimatoz	Sandoz	Approved (2018 EMA and FDA)	As per originator reference agent
M923		Momenta Pharmaceuticals	Ph 3 (NCT02581345)	Plaque psoriasis, rheumatoid arthritis
adalimumab-fkjp; MYL-1401A; FKB327	Hulio	Mylan, Fujifilm Kyowa Kirin Biologics	Approved (2018 EMA, 2020 FDA)	As per originator reference agent
adalimumab-afzb; PF-06410293	Abrilada; Amsparity	Pfizer	Approved (2019 FDA, 2020 EMA)	As per originator reference agent
adalimumab; CT-P17	Yuflyma	Celltrion Healthcare Hungary Kft	Approved (EMA 2021)	As per originator reference agent
adalimumab-aqvh; CHS-1420	Yusimry	Coherus BioSciences	Approved (FDA 2021)	As per originator reference agent
IBI303		Innovent Biologics	Ph 3 (NCT02893254)	Active ankylosing spondylitis
AVT02	Hukyndra; Libmyris	Alvotech/DKSH/Stada Arzneimittel	Approved (EMA 2021)	As per originator reference agent

one_letter_seq

three_letter_seq

post_translational_modifications

chemical_modifications

Document Information

Quality Inspection Report COA

Please input Lot number:

SDS-CN SDS-EN

Specification Sheet

Product Questions

See all

No questions yet. Be the first to ask the question!

Bibliography

1. Kempeni J. (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.. Ann Rheum Dis, 58 Suppl 1 (13): (I70-2). [PMID:10577977]
2. Wollheim FA. (2002) TNF inhibition as therapy for rheumatoid arthritis.. Expert Opin Investig Drugs, 11 (7): (947-53). [PMID:12084005]
3. Rau R. (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.. Ann Rheum Dis, 61 Suppl 2 (13): (ii70-3). [PMID:12379628]
4. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al.. (2016) Adalimumab in Patients with Active Noninfectious Uveitis.. N Engl J Med, 375 (10): (932-43). [PMID:27602665]
5. Kawalec P, Mikrut A, Wi?niewska N, Pilc A. (2013) Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.. Arch Med Sci, 9 (5): (765-779). [PMID:24273556]
6. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, Warrington S, Boyce M. (2017) Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.. Br J Clin Pharmacol, 83 (7): (1405-1415). [PMID:28133772]
7. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G et al.. (2016) A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.. Int J Rheum Dis, 19 (11): (1157-1168). [PMID:26176644]
8. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. (2017) Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.. Br J Dermatol, 177 (6): (1562-1574). [PMID:28755394]
9. Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.. Expert Opin Biol Ther, 18 (8): (921-930). [PMID:29962245]
10. Schreiber S, Yamamoto K, Muniz R, Iwura T. (2020) Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.. Pharmacol Res Perspect, 8 (3): (e00604). [PMID:32500668]

Shanghai Aladdin Biochemical Technology Co., Ltd

Sales Terms and Conditions ? ? ? ? Privacy Policy

Shanghai Public Network Security 31012002004058 Shanghai ICP preparation 09093490-2

All products sold on this website are only for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not for medicinal or edible purposes.